Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Peptides|January 18, 2006
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercializationMac E Hadley, Robert T DorrThe Journal of Pharmacology and Experimental Therapeutics|March 14, 2007
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cellsAlan Pourpak, Terry H Landowski, Robert T DorrClinical Lymphoma|January 13, 2004
Mood alterations in patients treated with chlorambucilSean T Hehn, Robert T Dorr, Thomas P MillerInvestigational New Drugs|July 9, 2008
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cellsBetty K Samulitis, Terry H Landowski, Robert T DorrLeukemia & Lymphoma|December 3, 2005
Correlates of imexon sensitivity in human multiple myeloma cell linesBetty K Samulitis, Terry H Landowski, Robert T DorrJournal of Medicinal Chemistry|December 30, 2003
Chemical basis for the biological activity of imexon and related cyanoaziridinesBhashyam S Iyengar, Robert T Dorr, William A RemersInvestigational New Drugs|September 17, 2013
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancersTerry H Landowski, Betty K Samulitis, Robert T DorrAnticancer Research|August 27, 2011
Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cellsBetty K Samulitis, Robert T Dorr, H-H Sherry ChowCancer Chemotherapy and Pharmacology|March 3, 2007
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell linesJulie Scott, Robert T Dorr, Betty Samulitis, et al.Biochemical Pharmacology|December 8, 2007
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)Lauren M Congdon, Alan Pourpak, Aluvia M Escalante, et al.Pageof 4